Executive Summary
Transseptal TMVR in mitral annular calcification finally has a registry footprint: the Sapien M3 system hit a 33.6% one-year death-or-HF-hospitalization rate in ENCIRCLE MAC, below the 45% performance goal and with 98.5% achieving ≤1+ MR — sobering numbers that still represent progress for a population with no good options. Simultaneously, the J-Valve transfemoral early feasibility study (N=25) reported 92% implant success and 95.5% freedom from more-than-trace AR at one year in pure aortic regurgitation, published in JSCAI. The Sheth ABC bicuspid sizing algorithm in Circulation: Cardiovascular Interventions showed 100% sensitivity and 89% specificity for predicting SAPIEN 3 root rupture across 170 patients at 15 centers — which tightens the case for CT-driven case selection in BAV TAVR, where guidelines remain unmoved.
- ABC algorithm flagged every aortic root rupture in a 170-patient bicuspid SAPIEN 3 cohort (sensitivity 100%, OR 374.5) [CCI].
- EARLY-TAVR updated results presented at New York Valves 2026 extend the case for early intervention in asymptomatic severe AS [TCTMD].
- Pooled TRI-SCORE meta-analysis (N=2,074) found TRI-SCORE ≥6 tripled 30-day mortality after tricuspid TEER (RR 3.17) [CRM].
- Severe aortic wall thrombus on pre-TAVR CT independently raised peri-procedural stroke risk nine-fold in a single-center cohort [CRM].
- MDCT annular sizing variability changed TAVI valve size selection in 40% of low-risk patients despite r >0.90 between operators [Sci Rep].
What to watch: Five-year follow-up of the EARLY-TAVR cohort and longer-term ENCIRCLE MAC data will determine whether early asymptomatic intervention and transseptal TMVR for MAC translate from acceptable one-year endpoints into durable survival benefit.
Aortic Valve (TAVR/TAVI)
[NOTABLE] The ABC bicuspid sizing algorithm reframes how operators should approach SAPIEN 3 in BAV anatomy. In a 15-center, 7-country retrospective analysis of 23 aortic root ruptures vs 147 controls (Sheth et al, CCI), any high-risk criterion — annular oversizing >10%, narrow intercommissural distance, tight sinus, or bulky leaflet calcium — caught 100% of ruptures (specificity 89.1%, diagnostic OR 374.5). Retrospective and case-control by design, but the effect size is enormous. This sits squarely against current guidelines: both ACC/AHA 2020 and ESC 2025 keep BAV TAVI at Class IIb, and SAVR remains preferred for younger BAV patients with aortopathy or heavy calcification. The ABC data don't change that — they sharpen who should never get a balloon-expandable valve.
Annular sizing reproducibility took a separate hit: across 50 low-risk SAVR patients, MDCT measurements correlated strongly between three expert readers (r >0.90), yet inter-observer differences shifted predicted TAVI valve size in 40% (Scientific Reports). Intraoperative sizers were systematically smaller than CT. In a field expanding TAVI to younger patients, 40% sizing disagreement among experts is not a rounding error.
EARLY-TAVR's updated results and the VA-CART Evolut analysis were presented at New York Valves 2026 (TCTMD; TCTMD). EARLY-TAVR underpins the ESC 2025 IIa upgrade for early intervention in asymptomatic severe AS; ACC/AHA 2020 still requires very severe AS, elevated BNP, or abnormal exercise testing. The gap is widening.
Pre-procedural CT now needs to look beyond the valve: severe aortic wall thrombus on baseline CT was present in 21.4% of stroke patients vs 3.3% of controls (multivariable OR 8.98) in a 148-patient single-center series (Galo et al, CRM). Retrospective, hypothesis-generating, but biologically plausible — and easy to look for.
The J-Valve transfemoral early feasibility study (N=25) reported 92% implant success, 8% 30-day death/disabling stroke, no cardiovascular deaths, and 95.5% ≤trace AR at one year for severe native AR. ESC 2025 lists TAVI for AR as Class IIb in inoperable patients; ACC/AHA 2020 doesn't address it. Twenty-five patients is hypothesis-generating, not practice-changing — but it's the first dedicated AR device data in a space where off-label TAVR performs poorly.
Mitral Valve (MitraClip, PASCAL, TMVR)
[NOTABLE] Transseptal TMVR for mitral annular calcification has its first multicenter, multinational dataset. The ENCIRCLE MAC registry (N=100, 36 centers, Sapien M3, presented by Mayra Guerrero at New York Valves 2026) hit a one-year composite of all-cause death or HF hospitalization of 33.6% — below the 45% performance goal — with 98.5% achieving ≤1+ MR and a mean 18.5-point KCCQ improvement. One-year mortality was 21.1%, stroke 7.4% (disabling 5.1%), and reintervention 11.4%. The MR reduction is real. The mortality is high because the patients are sick: mean STS PROM 8.4%, 73% NYHA III/IV, nearly half with prior AVR.
This sits in territory neither ACC/AHA 2020 nor ESC 2025 covers cleanly. ESC 2025 lists TMVI for degenerative MS with MAC as Class IIb at experienced centres. The surgical comparator for MAC patients is grim — most are turned down — but discussant Gorav Ailawadi cautioned post-commercial caution, and panelist Pedro Villablanca framed MAC as "stage 3/4 cancer" relative to native MR. Translation: 33.6% at one year is the best available, not good.
A separate transcatheter mitral replacement case using the Cardiovalve dedicated TMVR system was reported in JACC Case Reports, demonstrating fully transfemoral transseptal deployment in degenerative MR with unfavorable TEER anatomy. Case-report-level evidence, but the device race in TMVR is clearly accelerating.
On the TEER side, a striking advanced-heart-failure case used elective Impella 5.0 support during M-TEER to prevent afterload mismatch, with sustained NYHA I-II status at 3.5 years (JACC Case Reports). ESC 2025 elevated TEER for ventricular SMR to Class I; ACC/AHA 2020 keeps it at IIa. Neither addresses pre-procedural circulatory support — but case series like this define where the technology pushes next.
Tricuspid Valve (TriClip, TTVR)
TRI-SCORE has the meta-analytic weight to enter routine pre-T-TEER workup. A systematic review and meta-analysis of five observational studies (N=2,074; Rmilah et al, CRM) showed TRI-SCORE ≥6 tripled 30-day mortality (RR 3.17) and quadrupled 3-month mortality (RR 4.03) after tricuspid TEER, while also predicting less effective TR reduction (RR 0.75 for ≤2+ residual TR at 3 months). Observational data only, no RCT to confirm — but the consistency across studies is hard to ignore.
This matters in the context of ESC 2025's Class IIa, LOE A recommendation for transcatheter tricuspid treatment in high-risk symptomatic severe TR (TRILUMINATE Pivotal, Tri.Fr, TRISCEND II). ACC/AHA 2020 said nothing about transcatheter TR; the next update will need to. TRI-SCORE provides the gatekeeping function the field has lacked: it tells you which "high-risk symptomatic" patients are actually too late.
A separate cautionary tale from EHJ Cardiovascular Imaging documented paradoxical TriClip embolization from tricuspid valve to iliac artery — a reminder that the device complication profile is still being characterized.
Surgical vs. Transcatheter Comparisons
No head-to-head RCT today. The day's signals all favor refining transcatheter case selection rather than expanding indications: ABC algorithm for bicuspid SAPIEN 3, TRI-SCORE for tricuspid TEER, AWT for stroke risk, MDCT sizing imprecision. None of this overturns the surgical comparator. ESC 2025's lowered threshold for TAVI to age 70 with tricuspid AV and suitable anatomy assumes precise sizing and anatomical assessment — a 40% sizing-driven valve-choice disagreement among expert readers (Sci Rep) puts real friction on that assumption. ACC/AHA 2020's more conservative <65 SAVR-preferred cutoff looks more defensible the more we learn about pre-procedural CT variability.
A separate Italian registry (TAH, N=20) explored TAVI at centers without on-site cardiac surgery, with zero 30-day mortality. Single-arm, small, but raises a policy question both guidelines duck: how mandatory is the surgical backstop in 2026 when conversion-to-surgery rates approach zero in experienced hands?
Device & Technology
A modified UNICORN technique using balloon-assisted leaflet laceration for native-valve TAVR with bulky leaflet-tip calcification was reported in JACC Case Reports, extending electrosurgical coronary-protection strategies beyond valve-in-valve. A separate case described intra-annular self-expanding (Navitor Vision) deployment through a kinked aortic graft for valve-in-valve in a small surgical bioprosthesis (JACC Case Reports). Anteris's Perceval-related ARVF case (JCDD) underscores that sutureless surgical valves carry their own septal-injury profile — relevant context as Anteris pushes its own transcatheter program.
Polymer leaflet design got a computational boost from a melt-electrowriting fibre-reinforcement framework using FE-DOE (Biomimetics) — durability remains the unfinished story for both bioprosthetic SAVR and TAVI, and polymer is the long-game answer.
Industry & Market
The market-research projection of $24.07B in transcatheter valve replacement by 2034 (vocal.media) is consultant noise without clinical context — but the clinical news today is what should anchor those projections. EARLY-TAVR, ENCIRCLE MAC, and J-Valve EFS each represent indication expansion. ABC algorithm and TRI-SCORE represent the contraction of unselected expansion. Both move together.
Financial Analysis
Edwards's J-Valve transfemoral early feasibility data published in JSCAI matter strategically more than commercially in the near term — N=25 doesn't move revenue. But Edwards acquired JC Medical (the J-Valve developer) from Genesis MedTech in 2024, an acquisition reportedly behind the Trump administration's later block of Edwards's attempt to also acquire JenaValve. The dedicated-AR-device race is now an Edwards monopoly in the US public-company space, with JenaValve remaining private. EW also hit a 52-week high this week; the ENCIRCLE MAC Sapien M3 commercial approval (2025) and J-Valve data extend the structural-heart moat that supports the high multiple. Edwards trades at a trailing P/E of 48.5 — pricing in continued indication expansion.
Boston Scientific (-54% over six months) and Abbott (-24%) are bleeding on broader factors — the structural-heart franchises (ACURATE Neo2 for BSX, MitraClip/TriClip for ABT) aren't the proximate cause but aren't insulating either. Medtronic (-16%) shows VA-CART Evolut data this week (TCTMD) but the stock hasn't responded.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Price: $89.72 (+0.07% daily, +3.30% over 6 months), at 52-week high
- Market cap: $51.7B; trailing P/E 48.5, forward P/E 26.6; beta 0.87
- 52-week range: $72.30 – $91.65
- Analyst target: $96.92 (range $84–$110, 26 analysts); consensus buy
- Next earnings: July 23, 2026 (EPS est $0.74; revenue est $1.70B)
EW continues the structural-heart-pureplay rally. J-Valve EFS data published in JSCAI today and the ENCIRCLE MAC commercial-approval Sapien M3 footprint widen the indication map. With JenaValve blocked and JC Medical absorbed, Edwards owns the public-company AR-device space. The 48.5 trailing P/E demands continued execution — early intervention in asymptomatic AS (EARLY-TAVR) and TMVR for MAC are the two largest TAM expansions in the pipeline.
Medtronic (MDT)
- Price: $80.52 (+0.49% daily, -15.90% over 6 months)
- Market cap: $103.1B; trailing P/E 21.6, forward P/E 12.6; beta 0.60
- 52-week range: $73.31 – $106.33
- Analyst target: $98.00 (range $78–$121, 26 analysts); consensus buy
- Next earnings: August 18, 2026 (EPS est $1.39; revenue est $9.55B)
The Evolut platform delivered VA-CART real-world outcomes at New York Valves 2026, but MDT remains stuck near six-month lows. The Evolut Low Risk five-year durability data and DEDICATE underpin ESC 2025's age-70 TAVI threshold, but the stock isn't getting credit for the franchise.
Abbott (ABT)
- Price: $93.24 (+3.04% daily, -24.46% over 6 months)
- Market cap: $162.4B; trailing P/E 26.1, forward P/E 15.4; beta 0.62
- 52-week range: $81.97 – $137.49
- Analyst target: $116.54 (range $92–$135, 24 analysts); consensus buy
- Next earnings: July 16, 2026 (EPS est $1.28; revenue est $12.53B)
ABT bounced +3% today but remains down sharply over six months. MitraClip benefits structurally from ESC 2025's Class I upgrade for TEER in ventricular SMR; TriClip rides the ESC 2025 IIa for transcatheter TR. The franchise news is good; the stock action says investors are pricing other headwinds.
Boston Scientific (BSX)
- Price: $44.20 (-0.58% daily, -53.99% over 6 months)
- Market cap: $65.7B; trailing P/E 18.5, forward P/E 11.9; beta 0.56
- 52-week range: $43.89 – $109.50
- Analyst target: $75.00 (range $55–$106, 29 analysts); consensus buy
- Next earnings: July 29, 2026 (EPS est $0.83; revenue est $5.37B)
BSX is at six-month lows. The ACURATE Neo2 redo-TAVR case published today (JACC Case Reports) highlights the device-specific coronary-obstruction risk during valve-in-valve, a real long-term concern as that population grows.
Anteris Technologies (AVR.AX)
- Price: AUD $14.27 (-3.39% daily, +82.95% over 6 months)
- Market cap: $1.4B; forward P/E -6.54; beta 0.73
- 52-week range: $4.68 – $15.00
- Analyst target: $13.00 (1 analyst); no consensus recommendation
The biggest mover in the structural-heart universe. The DurAVR polymer-leaflet story sits in the durability-driven future the field is moving toward — pre-revenue, single-analyst coverage, but the polymer-valve thesis is real (see today's MEW polymer-leaflet modelling paper in Biomimetics).
Market outlook: Today's news favors the structural-heart leader (Edwards) over diversified med-tech. The pattern is consistent: indication expansion in AR, MAC, asymptomatic AS, and tricuspid is concentrating in companies with dedicated structural-heart franchises. Sizing and selection tools (ABC, TRI-SCORE) constrain volume growth from below while expanding what's safely possible at the top.
Clinical Trial Updates
The DRAGON-TAVI randomized trial design was published in Cardiology Journal, evaluating remote ECG monitoring as a diagnostic tool for post-TAVR conduction disturbance management. APOLO-VT (J Cardiovasc Electrophysiol) launched a digital-twin-guided VT ablation strategy in 60 SHD patients — not a valve trial, but relevant to the increasing arrhythmia comorbidity in post-valve populations.
Social & Conference Highlights
New York Valves 2026 dominated this week's clinical signal: ENCIRCLE MAC, EARLY-TAVR updates, VA-CART Evolut outcomes, and J-Valve EFS all presented or referenced. The conference is consolidating its role as the structural-heart pivot point of the year between ACC and TCT.
The next pivot: how ENCIRCLE MAC's 33.6% one-year composite holds at three and five years, and whether the ABC algorithm gets validated prospectively before BAV TAVI volume catches up to it. The field is no longer expanding indications without selection tools — and that's the right direction.